Sangamo Biosciences (SGMO) Tops Q4 EPS by 11c

Sangamo Biosciences (NASDAQ: SGMO) reported Q4 EPS of ($0.14), $0.11 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $8.9 million versus the consensus estimate of $3.91 million.

For earnings history and earnings-related data on Sangamo Biosciences (SGMO) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• UBS says bull market has further to run
• Wolfspeed (WOLF) Misses Q4 EPS by 174c; Offers Guidance